We believe that clinical adoption of psychedelic therapies represents an opportunity to reduce human suffering on an unprecedented scale.
The Psychedelic Action Task Force is a clinician- and scientist-led coalition working to redress the UK mental health crisis and provide solutions to its severe social and economic repercussions, namely, through the democratisation of access to psychedelic treatments in respect of which there is sufficient evidence of both safety and efficacy.
Founded by Prof. David Nutt and Alex Adams, Psychedelic Action will be advocating for evidence-based drug policy reform, conducting a revaluation of current clinical paradigms, and facilitating the integration of psychedelic therapy into the UK healthcare system, including the training of clinicians and therapists.
Executive Committee:
Prof. David Nutt, Alex Adams, Dr. Leyla Hussein OBE, Mabel Evans
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2024
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Psychedelic Action Task Force founded?
Psychedelic Action Task Force was founded in 2024.
What industry is Psychedelic Action Task Force in?
Psychedelic Action Task Force operates in Mental Health Care. Find similar Mental Health Care investors on gritt.io.
Find investors for your startup like Psychedelic Action Task Force
Gritt sends AI-personalised outreach to each investor — from your Gmail
